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Abstract
 
Efficient T cell activation is dependent on the intimate contact between antigen-presenting
cells (APCs) and T cells. The engagement of the B7 family of molecules on APCs with CD28
and CD152 (cytotoxic T lymphocyte–associated antigen 4 [CTLA-4]) receptors on T cells de-
livers costimulatory signal(s) important in T cell activation. We investigated the dependence of
pathologic cellular activation in psoriatic plaques on B7-mediated T cell costimulation. Patients
with psoriasis vulgaris received four intravenous infusions of the soluble chimeric protein
CTLA4Ig (BMS-188667) in a 26-wk, phase I, open label dose escalation study. Clinical im-
provement was associated with reduced cellular activation of lesional T cells, keratinocytes,
dendritic cells (DCs), and vascular endothelium. Expression of CD40, CD54, and major histo-
compatibility complex (MHC) class II HLA-DR antigens by lesional keratinocytes was mark-
 
edly reduced in serial biopsy specimens. Concurrent reductions in B7-1 (CD80), B7-2 (CD86),
CD40, MHC class II, CD83, DC–lysosomal-associated membrane glycoprotein (DC-LAMP),
and CD11c expression were detected on lesional DCs, which also decreased in number within
lesional biopsies. Skin explant experiments suggested that these alterations in activated or ma-
ture DCs were not the result of direct toxicity of CTLA4Ig for DCs. Decreased lesional vascu-
lar ectasia and tortuosity were also observed and were accompanied by reduced presence of
E-selectin, P-selectin, and CD54 on vascular endothelium. This study highlights the critical
and proximal role of T cell activation through the B7-CD28/CD152 costimulatory pathway in
maintaining the pathology of psoriasis, including the newly recognized accumulation of mature
DCs in the epidermis.
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Introduction
 
Psoriasis vulgaris is an inflammatory skin disease afflicting
 
z
 
2% of the population. It is likely to be mediated by acti-
vated T cells, which early within the course of disease are
present within the lesional skin in increased numbers (1, 2).
 
Portions of this work have been published in abstract form (1997. 
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Dendritic cells (DCs),
 
1
 
 an APC population uniquely capa-
ble of efficiently stimulating resting T cells (3), are also in-
creased in psoriatic lesions (4) and possess an activated phe-
notype (2, 5). Cytokines released from these activated T
cells and DCs are believed to contribute to the pathologic
changes induced in lesional keratinocytes (6, 7) and vascu-
lar endothelium (8, 9).
Cytotoxic T lymphocyte–associated antigen 4 (CTLA-
4)–immunoglobulin (CTLA4Ig; BMS-188667), a novel
soluble chimeric protein, binds to B7-1 (CD80) and B7-2
(CD86) expressed on APCs and thereby inhibits a second
signal required for optimal T cell activation (10–13).
CTLA4Ig inhibits skin APC and T cell functional interac-
tions
 
 
 
in vitro (5, 14). Administration of CTLA4Ig to pa-
tients with psoriasis vulgaris in a phase I trial produced a
dose-dependent improvement in skin lesions. 9 of 11 pa-
tients in the top dosing groups achieved a 50% or greater
decrease in psoriasis clinical scores (15). This use of
CTLA4Ig in psoriasis patients provides a unique opportu-
nity to ascertain the contribution of ongoing T cell costim-
ulation to the persistence of chronic cell-mediated inflam-
mation in a human disease (16). We will demonstrate here
that the B7-targeted disruption of APC and T cell interac-
tion effectively blocks T cell activation and reinstates a na-
scent phenotype to lesional tissue.
 
Materials and Methods
 
Patients.
 
A protocol outlining the use of CTLA4Ig (BMS-
188667) in patients with moderate to severe psoriasis was ap-
proved by the Institutional Review Boards of participating clini-
cal institutions. Patients providing informed consent for use of
the investigational agent were enrolled into this study if they had
a history of stable psoriasis vulgaris of at least 6-mo duration in-
volving 10–49% of total body surface area, and had failed at least
one prior antipsoriatic therapy. Before enrollment on study, sys-
temic retinoids were discontinued for at least 2 yr; investigational
drugs, methotrexate, cyclosporine, and systemic corticosteroids
were discontinued for at least 16 wk; phototherapy and photo-
chemotherapy were not administered for at least 4 wk; and topi-
cal treatments other than emollients were not administered for
two or more weeks. The baseline demographics of this patient
population were described in a previous publication (15).
 
CTLA4Ig (BMS-188667) Administration.
 
CTLA4Ig (BMS-
188667) was administered as a 1-h intravenous infusion on day 1
(week 1), day 3, day 16 (week 3), and day 29 (week 5). Four to
six patients were accrued to each of eight dose levels in this open
label dose escalation study: 0.5, 1, 2, 4, 8, 16, 25, and 50 mg/kg.
Patients were monitored continuously for a 4-h period after each
infusion and at weekly intervals during the first 8 wk of study,
then at biweekly to monthly intervals through day 176 (week
26). Safety, immunogenicity, pharmacokinetic, and biologic ac-
tivity assessments were performed at each visit.
 
Immunohistochemical Studies.
 
Samples for histological analysis
were obtained with a 6-mm punch biopsy from representative le-
sions before administration of CTLA4Ig (BMS-188667) and at
study days 8, 16, 36, and 78. Each specimen was split for routine
histopathology and for histochemical analysis on cryostat-cut
6-mm sections. Immunohistochemical staining procedures using
3-amino-9-ethylcarbazol as the chromagen were performed as
described previously (17). Antibodies used for histochemical anal-
ysis had the following specificities: CD3, CD25, HLA-DR,
CD1a, and CD80 (clones SK7, 2A3, L243, SK9, and L307, re-
spectively; Becton Dickinson), CD8 (clone OKT8; American
Type Culture Collection), CD86 and CD11c (clones FUN-1 and
B-ly6, respectively; BD PharMingen), CD54 (RR 1/1; Bio-
source International), CD40, P-selectin, and E-selectin (clones
G28.5, 5G4, and 5G11, respectively; Bristol-Myers Squibb),
CD83 (clone HB15a; Immunotech), DC–lysosomal-associated
membrane glycoprotein (DC-LAMP) and macrophage mannose
receptor (MMR) (gifts from Ralph Steinman, The Rockefeller
University), neutrophil elastase (clone 204; Biodesign), Factor
XIIIa (FXIIIa; Calbiochem), or laminin (clone 2E8; a gift from
Eva Engvall, La Jolla Cancer Research Foundation, La Jolla, CA).
Quantitative measures of epidermal area and length (used to com-
pute mean thickness) and cell numbers reactive with specific anti-
bodies were obtained using a Macintosh computer using public
domain IMAGE program from the National Institutes of Health
(http://rsb.info.nih.gov/nih-image).
 
DC Migration Studies.
 
Split thickness biopsies of psoriatic skin
lesions were obtained in The Rockefeller University General
Clinical Research Center using a protocol approved by The
Rockefeller University Institutional Review Board. Three psori-
atic patients, who provided informed consent and did not receive
infusions with CTLA4Ig (BMS-188667), underwent biopsy of
psoriatic lesional skin. Split thickness samples were also prepared
from the skin of four healthy donors undergoing corrective sur-
gery of face, breast, or abdomen. The skin was stored at 4
 
8
 
C and
used in the assays described below within 6 h of collection. Each
explant was trimmed (psoriatic lesional skin: 30-mm
 
2
 
; normal
skin: 400-mm
 
2
 
) and floated in 5–10 ml of culture medium. 3-d in
vitro cultures of skin explants were established with the subse-
quent preparation of single emigrant cell suspensions as described
previously (18). Skin explants were incubated in the presence of
either CTLA4Ig (100 
 
m
 
g/ml) or media alone throughout the
culture period.
 
Flow Cytometry.
 
Single cell suspensions of emigrant skin cells
were incubated with saturating concentrations of the following
mouse anti–human fluorochrome-conjugated antibodies, for 15
min at room temperature: PE-conjugated anti-CD3 (clone SK7;
Becton Dickinson); peridinin chlorophyll protein (PerCP)-conju-
gated anti-CD45 (clone 2D1; Becton Dickinson); allophycocya-
nin-coupled HLA-DR (clone L243; Becton Dickinson), and
FITC-conjugated anti-CD80 (clone L307; Becton Dickinson),
anti-CD86 (clone FUN-1; BD PharMingen), anti-CD40 (clone
5C3; BD PharMingen), or anti-CD1a (clone HI149; BD Phar-
Mingen). CTLA4Ig (100 
 
m
 
g/ml) was added before staining in some
experiments as a control for steric inhibition of binding of CD80-
and CD86-specific mAbs. The controls for nonspecific Ig binding
were mouse IgG1 directly conjugated to FITC (clone MOPC-21;
BD PharMingen), PE, or PerCP (clone X40; Becton Dickinson),
and IgG2a directly conjugated to allophycocyanin (clone X39;
Becton Dickinson). 5,000 DC-gated events (CD3
 
2
 
, DR
 
1
 
, CD45
 
1
 
)
were collected for quadruple staining on a FACSCalibur™ flow
cytometer (Becton Dickinson), and data were analyzed using
CELLQuest™ software (Becton Dickinson). For publication pur-
 
1
 
Abbreviations used in this paper:
 
 CTLA-4, cytotoxic T lymphocyte–associ-
ated antigen 4; CTLA4Ig, CTLA-4–immunoglobulin; DC, dendritic cell;
DC-LAMP, DC–lysosomal-associated membrane glycoprotein; ICAM,
intercellular adhesion molecule; LC, Langerhans cell; MFI, mean fluores-
cence intensity; MMR, macrophage mannose receptor; PerCP, peridinin
chlorophyll protein. 
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poses, flow cytometry profiles were scanned, converted to digital
files, and imported into Adobe Illustrator
 
®
 
 v8.0 for Macintosh
(Adobe Systems) where curve-fitting was performed.
 
Statistical Analysis.
 
Data were summarized as mean 
 
6 
 
SD.
Comparisons between experimental groups were performed us-
ing the two-sided Wilcoxon signed rank test for paired data. A
significance level of 5% was used for all comparisons.
 
Results
 
CTLA4Ig Administration Improves Psoriasis Clinical Activity.
 
Psoriasis patients receiving four infusions with the solu-
ble chimeric protein CTLA4Ig (BMS-188667) displayed a
dose-dependent improvement in their global clinical pa-
rameters of psoriasis (15). Though meaningful clinical re-
sponses were observed in all but the lowest dosing cohort,
the most consistent responses were observed in the top two
dose groups (CTLA4Ig 25 and 50 mg/kg dose). 9 of 11 pa-
tients accrued to these 2 dosing cohorts demonstrated a
50% or greater improvement from baseline psoriasis evalua-
tion. The duration of clinical response was sustained in
many cases throughout the 147-d median observation pe-
riod after the final CTLA4Ig infusion. Clinical quiescence,
therefore, often persisted well after the elimination of de-
tectable CTLA4Ig from the circulation. No discernible
changes in B7-bearing target cell populations or alterations
in lymphocyte subset distributions were observed in the
peripheral blood.
To ascertain the mechanisms by which the inhibition of
the CD28/CD152 T cell costimulatory pathway moder-
 
ated the chronic inflammatory cascade and resolved psori-
atic lesions, a series of immunohistochemical studies was
undertaken. Histologic samples were obtained from pro-
spectively identified lesions prestudy and at study days 8,
16, 36, and 78 after initiation of CTLA4Ig infusions.
 
Reduction in Intralesional T Lymphocyte Subsets and Neutro-
phils after Administration of CTLA4Ig.
 
The number of CD3,
CD25, and CD8 positively staining T lymphocytes was se-
rially reduced in specimens obtained after the initial (day 1)
infusion with CTLA4Ig in 9 of 11 patients accrued to the
2 top dosing cohorts (Fig. 1, A–I). The most rapid reduc-
tions were observed within the CD25
 
1
 
 (IL-2 receptor 
 
a
 
subunit) T cell subset. Normalization of intralesional T cell
counts correlated with meaningful clinical improvement in
these patients. T (CD3
 
1
 
) lymphocytes, including the CD8
 
1
 
and CD25
 
1
 
 subsets, were clustered in the papillary dermis
and the suprapapillary epidermis in baseline biopsies. At day
78, the few remaining T lymphocytes were predominantly
distributed within the dermis. Progressive epidermal thin-
ning was also evident in these serial biopsies.
Elastase-positive neutrophilic infiltrates were also de-
creased after the initiation of therapy (Fig. 1, J–L). At day 1,
neutrophils were detected in the papillary dermis and in the
stratum corneum. At subsequent biopsy time points, neu-
trophils appeared to be concentrated within the papillary
capillaries (Fig. 1 K; arrows). In general, the elimination of
neutrophils from psoriatic lesions occurred more rapidly
than that of T lymphocytes, and this population of cells was
no longer present in extravascular spaces on day 78.
Figure 1. Decrease in psoriatic
lesional leukocytic infiltrates after
administration of CTLA4Ig.
Representative immunohis-
tochemical findings in serial bi-
opsies at day 1 (top), day 36
(middle), and day 78 (bottom)
from prospectively identified le-
sions in 9 of the 11 patients ac-
crued to the CTLA4Ig 25 and 50
mg/kg dose levels. Illustrated in
A–L are data from a patient who
received CTLA4Ig 25 mg/kg/
dose. T cells present within the
lesion were detected by immu-
nostaining with mAbs to CD3
(A–C), CD25 (D–F), or CD8
(G–I). Serial reductions in T cell
infiltrates were observed after
initiation of CTLA4Ig infusions
(day 1) and were associated with
progressive epidermal thinning.
Neutrophilic infiltrates detected
by immunostaining with mAbs
to elastase (J–L) were also de-
creased in serial biopsies. At day
36 (K), neutrophils were largely
confined to capillaries in the
papillary dermis (arrows). Origi-
nal magnifications: 3200. 
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Reduction in Intralesional T Lymphocytes Is Associated with
Alterations in Keratinocyte Proliferation and the Diminished Ex-
pression of Keratinocyte Accessory Molecules.
 
Soluble factors
released from activated T lymphocytes are believed to con-
tribute to the hyperproliferation of keratinocytes within
psoriatic lesions (6, 7). Therefore, intralesional T lympho-
cyte counts were correlated with epidermal thickness in se-
rial lesional biopsies obtained from patients accrued to the
25 and 50 mg/kg dose groups. Peak reductions in intrale-
sional T lymphocytes were observed at day 78 with an 88%
mean decrease in the epidermal compartment (
 
P
 
 
 
, 
 
0.001)
and a 73% mean reduction in the dermal compartment
compared with baseline examination (
 
P
 
 
 
, 
 
0.001) (Fig. 2
A). A statistically meaningful decline in epidermal thickness
was observed as early as day 8 (19% reduction;
 
 P 
 
5 
 
0.016);
at day 78, a 56% mean percent reduction from baseline epi-
dermal thickness was observed (
 
P
 
 
 
, 
 
0.001). The decrease
in lesional epidermal T lymphocytes correlated most
closely with the observed reductions in epidermal thickness
(
 
r
 
 
 
5 
 
0.73). Individual patient correlation plots for each of
the four biopsies obtained after the day 1 infusion are illus-
trated in Fig. 2 B.
Keratinocytes, upon activation, are able to express a vari-
ety of cell surface proteins that are thought to play an im-
portant role in amplifying the cutaneous inflammatory re-
action in psoriasis, including the clonal expansion of
intralesional T cells (19–24). Membrane-bound and soluble
T cell factors induce these keratinocyte phenotypic alter-
ations (6, 19, 20). Therefore, a paracrine loop for intrale-
sional T cell activation may be provided by activated le-
sional keratinocytes. Accordingly, immunohistochemical
studies of select keratinocyte accessory molecules were un-
dertaken. At day 1, strong immunostaining with mAbs re-
active with CD40 was detected on lesional keratinocytes,
 
particularly in the suprapapillary areas. The CD40 expres-
sion on keratinocytes, colocalized with the marked expres-
sion of CD54 (intercellular adhesion molecule [ICAM]-1),
MHC class II HLA-DR antigens (Fig. 3, A, D, and G), and
the influx of juxtaposed T lymphocytes (Fig. 1, A, D, and
G). At day 78, clinically responding patients displayed weak
CD40 reactivity on the basal layer of keratinocytes. CD54
and HLA-DR expression were similarly markedly dimin-
ished within the day 78 biopsy specimens (Fig. 3, C, F, and
I). Clinically nonresponding patients did not demonstrate
discernible changes in their immunohistology from baseline
examination with regard to all serial immunohistochemical
studies incorporated in this study.
 
Presence of Mature DCs in Psoriatic Epidermis and Their Di-
minished Density after Administration of CTLA4Ig.
 
Kerati-
nocytes do not express B7 molecules, the ligands for
CTLA4Ig (25). Therefore, we studied the effects of
CTLA4Ig on epidermal Langerhans cells (LCs) and dermal
DCs, the predominant B7-bearing cells within the skin,
providing costimulatory signals for intralesional T cell acti-
vation (3, 5, 14, 26–31). We assessed whether the de-
creased number of intralesional T lymphocytes observed on
study could be partially attributed to a change in the num-
ber of skin DCs or their complement of accessory/costim-
ulatory molecules that have an upregulated expression on
mature DC.
The density of CD40, CD54, and HLA-DR staining on
intralesional DCs decreased progressively in clinically re-
sponding patients. Weak residual CD40, CD54, and HLA-
DR reactivity was evident on infiltrating dermal mononu-
clear cells at day 78 (Fig. 3, A–I). A diminished number of
FXIIIa-staining dermal DCs was also observed in clinical
responders (4), particularly in the upper reticular and papil-
lary dermis (Fig. 3, J–L).
Figure 2. Changes in psoriatic lesional T cell
numbers and keratinocyte hyperplasia across the
11 patients accrued to the CTLA4Ig 25 and 50
mg/kg dose groups. (A) Mean percent decrease
in values for epidermal thickness (black squares)
and numbers of T cells within the epidermis
(red diamonds) or dermis (blue circles) com-
pared with baseline (day 1) are illustrated over
the first 78 d of the study period. Asterisks indi-
cate statistical significance (*P , 0.05; **P ,
0.001). P values were based on a two-sided t test
for no change at the indicated study day com-
pared with day 1. (B) Correlation plots of the
percent change in infiltrating epidermal or der-
mal T cells versus percent change in epidermal
thickness for each patient at all sampling time
points. Individual data points are an average
derived from triplicate analyses. Epidermal
thickness was calculated by quantitating the
cross-sectional surface area beneath a 1-mm lin-
ear region of a representative histological section
using computer-assisted image analysis. Positive
correlations between the change in T (CD31)
cell numbers and epidermal thickness were evi-
dent (epidermal CD31: r 5 0.73; dermal CD31:
r 5 0.61). Discordant responses characterized by reductions in epidermal thickness that were not accompanied by similar reductions in T cell numbers
within a specific compartment are indicated (open red squares). 
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The morphology of the lesional DC population also
changed over time. DCs possessing long, branching pro-
cesses evident at the time of the initial skin biopsy (Fig. 3,
G and J, inset) were replaced with a population of smaller
cells that had less numerous, clipped processes (Fig. 3,
 
 
 
H, I,
K, and L, inset). The morphological features of this latter
population resembled immature DCs. mAbs to CD1a, ex-
pressed on immature but not mature LCs (30, 32), dis-
played serial increases in reactivity predominantly within
the suprabasal layer of the epidermis, in the majority of pa-
tients accrued to the top two dosing cohorts (Fig. 4, A–C).
Thus, CD1a positivity originally “displaced” to the upper
zone of the thickened epidermis at day 1 was replaced by a
more equitable CD1a staining distribution at day 78.
Conversely, there was a progressive decrease in the in-
tensity of staining with mAbs reactive with CD80 (B7-1)
and CD86 (B7-2) in serial biopsies (Fig. 4, D–I). Notably,
 
reagents selected for immunohistochemical studies of
CD80 and CD86 expression did not bind to the same B7
epitopes as CTLA4Ig (data not shown; reference 33). At
day 1, CD80 and CD86 staining was present in both the
epidermis and dermis (Fig. 4, D and G). Day 78 biopsy
specimens, however, revealed low level staining of DCs
only within the dermal compartment, with slightly higher
density staining for CD86 than CD80 (Fig. 4, F and I).
To confirm that the diminished density of DC activa-
tion markers and the modified DC morphology within le-
sional biopsies were associated with decreased numbers of
mature DCs, immunohistochemical studies of serial le-
sional biopsies were performed using DC-restricted, matu-
ration-associated markers (CD83, DC-LAMP, and MMR)
and the leukocyte integrin CD11c. CD83 and DC-LAMP,
expressed at high levels on mature DCs (34, 35), displayed
markedly increased staining in day 1 lesional biopsy speci-
Figure 3. Diminished immu-
nohistochemical detection of
CD40, ICAM-1, HLA-DR, and
FXIIIa in psoriatic lesional skin
after administration of CTLA4Ig.
Keratinocytes within the supra-
papillary regions (arrows) and
DCs displayed marked upregula-
tion of expression of CD40,
ICAM-1 (CD54), and HLA-DR
at day 1 (top), which serially de-
creased at study days 36 (middle)
and 78 (bottom). Superficial cap-
illaries in untreated psoriatic le-
sions also exhibited increased
ICAM-1 and CD40 staining (ar-
rowheads; A and D), which was
reduced at days 36 (B and E) and
78 (C and F). Phenotypic alter-
ations of lesional DCs stained
with mAbs to HLA-DR and
FXIIIa are observed at days 36
and 78 after the initial infusion
(G–L). Higher magnification
views of the boxed regions are
shown in the inset areas in G–L,
and demonstrate a progressive
decrease in the number and
length of branching processes ra-
diating from the cell body (den-
dricity) of the stained cells. Re-
sults shown are from serial
biopsies of a single lesion in a pa-
tient administered CTLA4Ig 25
mg/kg and are representative of
the nine patients achieving a
50% or greater improvement in
clinical scores. Original magnifi-
cations: (A–F) 3400; (G–L)
3200; (G–L, insets) 3800. 
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mens in a pattern similar to CD80 and CD86 expression
(Fig. 5, A and C). Little residual staining was evident at day
78 in clinical responders (Fig. 5, B and D). In contrast, un-
affected skin from psoriatic patients showed no significant
staining in the epidermis or dermis with these antibodies
(data not shown). CD11c, expressed at high levels on some
DCs (36), demonstrated increased staining on DCs in both
the dermis and epidermis at day 1 (Fig. 5 E). Marked re-
ductions in CD11c immunoreactivity were observed at
day 78 in clinical responders, with residual staining exclu-
sively in the dermal compartment (Fig. 5 F). A pattern of
CD11c immunoreactivity similar to the day 78 biopsy
findings was observed in nonlesional biopsies from psori-
atic patients (data not shown). MMR, a carbohydrate-rec-
ognizing receptor important in the uptake and delivery of
antigens to MHC class II compartments for antigen pro-
cessing and presentation, is expressed on immature DCs.
MMR expression on DCs is downregulated in vitro by in-
flammatory stimuli (37). Immunohistochemical studies in
human tissue have not detected expression of MMR on
LCs (38). Day 1 and 78 biopsy specimens demonstrated
MMR staining within the dermis with little apparent alter-
Figure 4. Increased CD1a reac-
tivity and reduced CD80 and CD86
expression in psoriatic lesional biop-
sies after administration of CTLA4Ig.
Serial biopsies were obtained from
the perimeter of a single lesion in a
patient accrued to the CTLA4Ig 25
mg/kg dose level, and are represen-
tative of the histological findings in
the clinical responders within the 25
and 50 mg/kg dosing cohorts. An
increasing density of CD1a1 epider-
mal LC staining was observed after
initiation of treatment (A–C). Posi-
tive CD80 and CD86 immunoreac-
tivity was seen in both the epidermis
and dermis at day 1 (D and G). Di-
minished staining for CD80 and
CD86 is seen at day 36 (E and H).
At day 78, CD80 expression was no
longer detectable within the epider-
mis, and minimal CD801 staining
was present in the dermis (F). A low
level of staining for CD86, predomi-
nantly within the dermis, was
present at day 78 (I). Original mag-
nifications: 3400. 
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ation in the density of staining (Fig. 5, G and H). There-
fore, psoriatic epidermis, and to a lesser extent psoriatic
dermis, were heavily infiltrated with activated/mature
DCs. Lesional biopsies at day 78 possessed a lower density
of the requisite accessory/costimulatory molecules for T
cell activation compared with pretreatment biopsies. These
findings may also be contributory to the observed reduc-
tion in lesional T cells.
 
Addition of CTLA4Ig to Normal and Psoriatic Skin Explant
Cultures Does Not Affect DC Maturation, Migration, or Sur-
vival.
 
The diminished incidence of mature DCs in serial
biopsies could be attributed to either (a) direct toxicity of
CTLA4Ig for DCs or (b) indirect effects of CTLA4Ig on
DCs resulting from impaired T lymphocyte activation,
with secondary effects on DC maturation, survival, and/or
recruitment (39–41). To distinguish between these possi-
bilities, we performed several experiments in which the
migration/maturation in vitro of DCs from split thickness
skin was conducted in the presence or absence of saturating
concentrations of CTLA4Ig (10, 42–49).
The harvest of DCs from explant cultures was un-
changed in the presence of CTLA4Ig. The mean recovery
of emigrating cells across the seven paired experiments (le-
sional and normal skin) was 1.37 
 
3
 
 10
 
5
 
 in the presence of
CTLA4Ig or 1.41 
 
3
 
 10
 
5
 
 in control cultures (
 
P
 
 
 
5 
 
0.447).
Approximately 60% of exfiltrators were CD3
 
2
 
HLA-DR
 
1
Figure 5. Alterations in immunohistochemical markers of DC maturational status in psoriatic lesional biopsies after CTLA4Ig administration. Biopsy
material obtained at day 1 (top) and day 78 (bottom) from a patient accrued to the CTLA4Ig 25 mg/kg dose level are illustrated and were reflective of the
changes observed in all clinical responders. The DC-restricted markers CD83 and DC-LAMP, expressed at high levels on mature DCs, demonstrated an
increased magnitude of staining in both the epidermis and dermis at day 1 (A, C, and Day 1 Dermis DC-LAMP). Marked reductions in the density of
staining for both CD83 and DC-LAMP were observed; little residual staining was evident at day 78 (B, D, and Day 78 Dermis DC-LAMP). Immunore-
activity for the leukocyte integrin CD11c, abundantly expressed on DCs, was also decreased within the epidermal and dermal compartments at day 78
compared with day 1 (E and F). Residual CD11c reactivity was restricted to the dermis at day 78. The population of immature DCs characterized by
MMR positivity was distributed exclusively within the dermal compartment and displayed small decreases in immunoreactivity at day 78 compared with
baseline examination (G and H). Original magnifications: (A, B, E–H) 3400; (C and D) 3800. 
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Table I.
 
Characterization of Skin DC Exfiltrators after 3 d of Culture
 
2
 
CTLA4Ig
 
1
 
CTLA4Ig
Skin explant
source
Cell surface
protein
Mean percentage of
CD3
 
2
 
HLA-DR
 
1 
 
CD45
 
1 
 
cells 
 
6 
 
SD MFI 
 
6 
 
SD
Mean percentage of
CD3
 
2
 
HLA-DR
 
1
CD451 cells 6 SD MFI 6 SD
Normal CD86 93.7 6 2.6 109.2 6 54.4 91.1 6 8.0 92.0 6 38.6
(n 5 4) CD80 60.7 6 11.8 35.6 6 21.8 44.0 6 15.1 22.4 6 10.9
CD40 72.0 6 7.6 33.3 6 16.0 71.2 6 10.8 31.6 6 14.2
CD1a 38.2 6 13.8 40.3 6 24.1 35.8 6 18.3 33.0 6 18.8
Psoriatic lesion CD86 75.9 6 10.2 135.8 6 51.6 83.2 6 11.9 158.0 6 61.0
(n 5 3) CD80 33.0 6 2.2 61.4 6 38.4 38.6 6 18.9 57.2 6 63.3
CD40 53.6 6 9.7 54.0 6 4.2 62.8 6 10.2 53.6 6 35.2
CD1a 43.3 6 3.3 75.2 6 40.0 34.6 6 21.6 52.1 6 40.9
Skin explants were cultured for 3 d either in media alone or with CTLA4Ig (100 mg/ml). Exfiltrators were quadruple-stained with mAbs reactive
against CD3, HLA-DR, CD45, and a panel of mAbs to CD86, CD80, CD40, or CD1a. Values represent mean 6 SD from independent experiments
of either the percentage of the total DC population possessing a given cell surface protein or the MFI for each of these proteins (n 5 4 normal skin;
n 5 3 psoriatic lesional skin). No significant difference between paired data sets was apparent.
CD451 regardless of the culture conditions (control mean
percent: 58.2 6 13.2; CTLA4Ig mean percent: 62.8 6
18.4; P 5 0.375). Cell viability in all experiments was
.90% as assessed by trypan blue exclusion. Therefore, the
presence of CTLA4Ig in the culture medium had no major
effect on the migration or survival of DCs from skin ex-
plants after 3 d of incubation.
Flow cytometric analyses of DCs emigrating either un-
der control conditions or in the presence of CTLA4Ig
failed to demonstrate significant differences in the levels of
CD86, CD80, CD40, or CD1a expression (Table I, and
Fig. 6). The proportion of CD32HLA-DR1CD451 cells
expressing each of these cell surface proteins was equiva-
lent across the paired experimental conditions. Further
fractionation of the CD32CD451 emigrating cell popula-
tion into high and medium HLA-DR expression indicated
that the CD80/CD86 mean fluorescence intensities (MFIs)
correlated with the level of HLA-DR expression after
culture of skin explants but not with the presence of
CTLA4Ig during culture (data not shown). DCs, upon ac-
tivation or emigration from explants, are known to in-
crease in size (43). Forward scatter flow cytometric analy-
ses failed to discern a difference in the mean cell size when
comparisons were made between those explants cultured
in the presence of CTLA4Ig versus media alone (data not
shown). These data indicated that the maturation of DCs
and their acquisition of costimulatory/accessory molecules
were not inhibited by the presence of CTLA4Ig in short
term culture. The diminished density of DC activation/
maturation markers and the modified DC morphology ob-
served on study are therefore likely attributable to an al-
tered lesional milieu resulting from decreased T cell activa-
tion, with secondary effects on DC extravasation into skin
and/or DC maturation.
T Cell Costimulatory Blockade Reduces Lesional Vascular En-
dothelial Selectin and Integrin Expression. Due to the inabil-
ity of the skin explant model to examine the possible effects
of CTLA4Ig administration on dermal vasculature and leu-
kocyte recruitment, immunostaining with antibodies reac-
tive to laminin (present in the basement membrane of
blood vessels), selectins, and integrins was undertaken. E-
and P-selectin (CD62E, CD62P) mediate the initial tether-
ing to, and rolling on, endothelium by neutrophils, T cells,
and DCs. These selectins are key contributors to the re-
cruitment of skin-homing T cells and DCs (40, 41, 50, 51).
Their expression is upregulated after endothelial exposure
to a variety of inflammatory cytokines, including TNF-a,
IFN-g, IL-1b, and IL-4 (8, 9). CD54 mediates the firm
adhesion of tethered leukocytes to endothelium, and its
expression is upregulated by many of the same cytokines
(52, 53).
Lesional vessels displayed progressively reduced ectasia
and tortuosity after day 1 infusions with CTLA4Ig (Fig. 7,
A–C). At day 1, CD62E and CD62P were strongly ex-
pressed in the superficial and deep vascular plexus. Expres-
sion of both selectins was diminished in serial biopsy speci-
mens (Fig. 7, D–I). Though modest decreases in CD62P
immunoreactivity were selectively observed in the superfi-
cial capillaries at days 36 and 78, these changes were de-
tected consistently across all clinically responding patients.
CD54 also displayed progressively decreased vascular im-
munoreactivity (Fig. 3, D–F). Downmodulation of these
vascular adhesion molecules likely impaired the ability of
endothelial cells to activate and recruit circulating leuko-
cytes to the psoriatic lesions, as evidenced by the dimin-
ished inflammatory infiltrate present at day 78. Human en-
dothelial cells do not express CD80 or CD86 (54). Thus, it
appears that the observed immunohistochemical changes689 Abrams et al.
were indirectly mediated through the binding of CTLA4Ig
to other local cellular B7-bearing targets.
Discussion
Our findings support the hypothesis that T cell activa-
tion is a critical and proximal event in the complex chronic
inflammatory cascade that culminates in the generation of
psoriatic plaques. To our knowledge, this is the first report
documenting the accumulation of mature DCs in a human
autoimmune target organ, the skin. Additionally, the reso-
lution of activated phenotypes on lesional keratinocytes,
DCs, and vascular endothelium after T cell costimulatory
blockade has not previously been reported. Thus, these
data expand upon our prior observations (15) and provide
possible mechanisms for the observed durable reduction in
intralesional T cells after administration of CTLA4Ig. We
have demonstrated that a reduced capacity for lesional T
cell clonal expansion (due to reversion of the lesional skin
APC population to a less mature/immunocompetent state)
and decreased vascular recruitment may both have been
contributory factors. These observations suggest that clini-
cal activity in this chronic autoimmune disease is depen-
dent on the continued activation of T cells.
Many models have been proposed to explain the inter-
play of keratinocytes with lesional T cells in the immuno-
pathogenesis of psoriasis. The upregulated expression of
MHC class II HLA-DR antigens on activated keratinocytes
could be regarded as an in vivo bioassay for the presence of
IFN-g released from activated T cells (6, 22). The ade-
quacy of keratinocytes to provide T cell activation signals,
however, has been a matter of some debate (55, 56). The
clinical resolution of psoriatic lesions after the specific dis-
ruption of B7 engagement with CD28/CD152 on T cells
has demonstrated that keratinocytes, which do not express
detectable B7, are not sufficient for perpetuating T cell ac-
tivation in psoriatic lesions.
Though the role of CD28/CD152 costimulation in T
Figure 6. Four-color flow cytometry analysis of emi-
grating leukocytes from normal and psoriatic lesional skin
explants. DCs (CD32DR1CD451) emigrating from nor-
mal skin (A) or psoriatic lesional skin explants (B) after 3 d
of culture were analyzed for expression of CD80, CD86,
CD40, or CD1a, and the results were plotted as histograms
of cell number versus log10 fluorescence. Isotype controls
for the DC population gates (CD32DR1CD451) used in
the two series of analyses are illustrated in A and B (red
lines). Cultures were performed with media alone (blue lines)
or in the presence of CTLA4Ig (100 mg/ml; green lines).
The data in A are representative of four independent ex-
periments with normal skin explants; data in B are compa-
rable to three independent experiments with psoriatic le-
sional skin. The results from all experiments are summarized
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cell activation and cytokine production is well understood
(11–13), comparatively little is known regarding the possi-
ble direct effects of this pathway on DC activation. In this
study, we have demonstrated that the presence of saturating
CTLA4Ig concentrations in short term skin explant cul-
tures did not impair DC maturation, migration, or survival.
These ex vivo data contrast with the immunohistochemical
observations in serial biopsies harvested over a 78-d period
after systemic administration of CTLA4Ig. The clinical
samples displayed a progressively less mature complement
of lesional DCs. The apparently conflicting observations
suggest that CTLA4Ig did not block DC activation
through direct inhibition of the B7 axis on DCs. Instead,
these data support a model in which the primary blockade
of T cell costimulatory signals leads to progressive diminu-
tion in the number, activation status, and cytokine elabora-
tion of lesional T cells, with secondary effects on keratinocyte
activation and cytokine release. A gradual transformation of
the skin microenvironment ensued. Under this scenario,
immature DCs recruited to lesional skin after initiation of
CTLA4Ig infusions presumably could no longer acquire
sufficient stimuli required to be optimally activated, further
compromising T cell activation signals. This model is in ac-
cord with the view of DCs as the consummate immuno-
logic “rheostats,” integrating a variety of activating signals,
which ultimately “tune” the capacity to stimulate T cells
(29). The cadence of the clinical response in this study was
slower than that observed with antipsoriatic agents that di-
Figure 7. Alterations in psoriatic
lesional vascular immunohistology in
serial cryostat sections after adminis-
tration of CTLA4Ig. Illustrated in
A–I are representative immunohis-
tochemical findings in biopsies ob-
tained at day 1 (top), day 36 (mid-
dle), and day 78 (bottom) from the
perimeter of a single lesion in clini-
cally responding subjects accrued to
the CTLA4Ig 25 and 50 mg/kg dose
levels; data shown are from one sub-
ject accrued to the 50 mg/kg dose
level. Immunostaining with mAbs to
laminin (A–C) present in the base-
ment membrane of blood vessels
(and epidermis) illustrates the pro-
gressive decrease in lesional vascular
ectasia and tortuosity after CTLA4Ig
administration. Increased E-selectin
(CD62E) and P-selectin (CD62P)
reactivity was noted in superficial
(arrows) and deep dermal vessels (ar-
rowheads) within chronically in-
flamed psoriatic skin at day 1 (D and
G). E-selectin staining decreases seri-
ally in both the superficial and deep
dermal vascular beds after adminis-
tration of CTLA4Ig (E and F). Ex-
pression of P-selectin is selectively
decreased in expression in the super-
ficial capillaries at days 36 and 78.
Original magnifications: 3200.691 Abrams et al.
rectly inhibit T cell activation and may be explained by
these observations (15, 57, 58).
Our immunohistochemical data indicate that T cell co-
stimulatory signals delivered through B7/CD28 are pivotal
in creating a microenvironment, which facilitates the acti-
vation of tissue DCs and the perpetuation of autoimmune
inflammation. However, these B7/CD28 signals in isola-
tion are not likely sufficient to initiate a chronic inflam-
matory cascade. The key requirements in constructing a
microenvironment conducive to T cell–mediated, organ-
specific autoimmune inflammation have been characterized
in transgenic models of pancreatic islet b cell inflammation.
Autoimmune inflammation of the pancreas in these animals
requires not only ectopic and/or increased expression of
CD80 but also either a genetically predisposed host (59),
increased levels of autoantigen and autoreactive T cells
(60), elevated MHC class II antigens (61), or enhanced lev-
els of an inflammatory cytokine (62). Mice expressing any
of these transgenes alone maintain normal pancreatic islet
architecture (60, 63, 64). A repertoire of inflammatory
stimuli analogous to this array of transgenes was identified
within the day 1 psoriatic lesional tissue. At day 78, the in-
trinsic T cell activating capacity was likely vastly different,
with lesional mononuclear cells possessing fewer of the
requisite class II antigens, accessory and costimulatory mol-
ecules for T cell activation. The downregulation via B7-
CD28/CTLA-4 blockade of a variety of proinflammatory
stimuli required for disruption of immunologic homeostasis
may explain the profound and durable clinical response,
well beyond the active treatment period, when contrasted
with other T cell–based therapies (15, 17). Additional ex-
planations for the durable response could include the possi-
ble induction of tolerance or the emergence of regulatory
T cells. Currently, no data exist in support of either of
these possible explanations.
In addition to the functional modulation of the T cell
activating capacity of lesional APCs, the alteration in en-
dothelial expression of CD54, E-selectin, and P-selectin
likely impaired the ability to recruit neutrophils, lympho-
cytes, and DCs to inflamed skin (40, 41, 50, 51). These se-
lectins and integrins have been demonstrated to be impor-
tant in the large scale influx of mononuclear cells to a
variety of other inflamed tissues including synovium and
respiratory tract (51, 65). Their presence on vascular endo-
thelium at heightened levels is important in the reseeding
of peripheral tissues with DCs to replenish the pool of tis-
sue DCs lost through DC migration–invoking stimuli (46,
48). Thus, vascular recruitment of effector cells, an addi-
tional common pathway important in sustaining chronic
inflammation, is also potentially impacted by B7/CD28 co-
stimulatory blockade.
In summary, we have shown that CTLA4Ig blockade of
the B7-CD28/CD152 pathway of T cell costimulation in
patients with psoriasis modulates the state of chronic in-
flammatory activation of T cells, DCs, and endothelial cells
in psoriatic plaques. These observations could have impor-
tant implications for the treatment of other acute or
chronic T cell–mediated diseases, where these effector cells
may play an important role in the pathogenesis of the dis-
ease.
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